Tag - ZOM

Markets

Dawson James starts Zomedica at buy; PT $6

Dawson James initiated coverage of Zomedica (NYSEA:ZOM) with a “buy” rating and price target of $6. The stock closed at 20 cents on Jan. 5. Analyst Jason Kolbert writes that Zomedica is positioning itself as a leading...

January 6, 2023

Executive Moves

Gerald Solensky resigns as Zomedica CEO; Shameze Rampertab named interim CEO

Gerald Solensky, Jr. has resigned as CEO, chairman and a director of Zomedica Pharmaceuticals (NYSE American, TSXV:ZOM), effective immediately. He will continue as a consultant to the company’s operating...

December 3, 2019

Tag - ZOM

Dawson James starts Zomedica at buy; PT $6

Gerald Solensky resigns as Zomedica CEO; Shameze Rampertab named interim CEO

General

More